Back to search results

PHACKs Study: Hydration and Potassium for Cardiovascular and Kidney Health

This study, called PHACKs, is looking at how drinking more water and taking potassium supplements might affect blood pressure and risk factors for heart and kidney disease. You would be given cases of water and asked to drink at least an extra liter (about 4 cups) per day. You would also receive 2000 mg of potassium chloride powder. Researchers will measure changes in your urine (pee) to see how these interventions affect your hydration over two weeks. This study is for people aged 18 to 30 who have blood pressure no higher than 150/90 mmHg, a BMI below 35 kg/m2, and no major health conditions like diabetes or heart disease. The study aims to enroll 40 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 40 participants.
What's involved
You would be instructed to drink at least an extra 1 liter of water per day and take 2000 mg of potassium chloride powder. Your urine will be measured after two weeks of these interventions.
Compensation
Not stated in the trial record.
Follow-up
Your urine will be measured after two weeks of the hydration interventions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06062017

Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)

Recruiting
NAAges 18–30InterventionalPrevention
Auburn University
~40 participants
Updated 2025-02-27 on ClinicalTrials.gov
What's tested:Water and Potassium supplementation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Urine specific gravity
Measured over Change score from habitual consumption to after the hydration interventions (2 weeks)
+7 more outcomes measured

Conditions

Blood Pressure
Hydration
Vascular Disease Risk

Explore related trials

Chronic Kidney DiseaseHypertensionVascular Disorder

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Austin T Robinson, Ph.D. · STUDY_DIRECTOR · Indiana University
  • L. Bruce Gladden, Ph.D. · STUDY_DIRECTOR · Auburn University

Who to contact

Nina L Stute, M.S.
[email protected]
9373071608
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Between the ages of 18-30 years
Resting blood pressure no higher than 150/90 mmHg
BMI below 35 kg/m2
Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.

Exclusion

Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood.
Are currently pregnant or trying to become pregnant.
take any of the following medications that are contraindicated with potassium supplementation:
Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan
Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen
Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol
Calcineurin inhibitors: Cyclosporine
Heparin (or other blood thinning medications)

What this trial measures

  • Urine specific gravityChange score from habitual consumption to after the hydration interventions (2 weeks)

    24 urine samples will be aliquoted and assessed for urine specific gravity (unitless)

  • Urine osmolalityChange score from habitual consumption to after the hydration interventions (2 weeks)

    24 urine samples will be aliquoted and assessed for urine osmolality in mOsm/kg (AI Osmometer 3D3)

  • Urine flow rateChange score from habitual consumption to after the hydration interventions (2 weeks)

    24 urine samples will be assessed for urine flow rate based on urine volume and self-reported collection time (ml/min).

  • Plasma copeptinChange score from habitual consumption to after the hydration interventions (2 weeks)

    Plasma copeptin concentration (picomoles per liter) from a resting blood draw

  • 24-hour ambulatory blood pressureChange score from habitual consumption to after the hydration interventions (2 weeks)

    Participants will wear an Oscar2 (with SphygmoCor) ambulatory blood pressure monitor on their upper arm for up to 24-hours preceding their study visit to measure systolic and diastolic blood pressure. The purpose of the ambulatory blood pressure monitoring is to determine blood pressure regulation over an entire day. This blood pressure monitor will be set to automatically take blood pressure every 20 minutes. The monitor records and saves each blood pressure measurement automatically.

  • Pulse wave velocityChange score from habitual consumption to after the hydration interventions (2 weeks)

    The investigators will use the SphygmoCor XCEL system to assess pulse wave velocity (PWV meters per second). A high-fidelity transducer is used to obtain the pressure waveform at the carotid pulse. Distances from the carotid artery sampling site to the femoral artery (upper leg instrumented with a thigh cuff for oscillometric sphygmomanometry), and from the carotid artery to the suprasternal notch will be recorded. PWV will be expressed as cm/s.

  • Pulse wave analysisChange score from habitual consumption to after the hydration interventions (2 weeks)

    The investigators will use the SphygmoCor XCEL system to assess pulse wave analysis (PWA) The sampling site is the brachial artery (upper alarm instrumented with a cuff for oscillometric sphygmomanometer). PWA will be expressed as a percentage (calculated as augmentation pressure divided by the pulse pressure).

  • Brachial blood pressureChange score from habitual consumption to after the hydration interventions (2 weeks)

    Seated rachial blood pressure will be measured triplicate after at least 5 minutes of rest using an oscillometric device (Suntech CT 40)